Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biopharmaceutical company in the immuno-oncology field, and this news page aggregates company announcements, clinical updates, and corporate developments related to its oncolytic immunotherapy programs. Genelux focuses on developing next-generation oncolytic vaccinia virus immunotherapeutic product candidates, led by its proprietary asset Olvi-Vec (olvimulogene nanivacirepvec).
News about Genelux frequently highlights progress in its clinical pipeline, including the Phase 3 OnPrime/GOG-3076 registrational trial in platinum-resistant/refractory ovarian cancer, the Phase 2 VIRO-25 trial in advanced or metastatic recurrent non-small cell lung cancer, and the Phase 1b/2 Olvi-Vec-SCLC-202 trial in recurrent or progressive small cell lung cancer. Company releases also describe interim data from these studies, such as observed anti-tumor activity, disease control rates, and tolerability of systemically administered Olvi-Vec in lung cancer settings.
In addition to clinical data, investors can find updates on public offerings of common stock, use of proceeds for research and development and clinical trial expenses, and governance-related items such as executive appointments and equity incentive plan changes. SEC-related disclosures, conference participation, and fireside chats with analysts are also common topics in Genelux’s news flow.
By following GNLX news, readers can track how Genelux advances its CHOICE™ platform-derived pipeline, how Olvi-Vec is being evaluated across multiple solid tumor indications, and how corporate actions support its late clinical-stage development strategy. This page provides a centralized view of the company’s press releases and public communications for those monitoring its progress in oncolytic viral immunotherapy.
Genelux reported its first-quarter 2024 financial results and provided updates on its business activities. The company is progressing with its pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer and plans to expand its use into other cancer indications. Genelux is also enrolling patients in clinical trials for non-small cell lung cancer and recurrent small cell lung cancer. The company filed a shelf registration statement to offer up to $300.0 million in common stock, preferred stock, debt securities, and warrants. Financially, Genelux had $19.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Research and development expenses increased by $1.2 million year-over-year, while general and administrative expenses increased by $0.3 million in the first quarter of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.